Literature DB >> 12921646

[Down-regulation of Toll-like receptor 4 is related to the tolerance to lipopolysaccharide in rat alveolar macrophages].

De-ming Zhang1, Yong-wang Li, Bao-ling Mao, Gui-sheng Qian.   

Abstract

OBJECTIVE: To explore the change of expression of Toll-like receptor 4 (TLR(4)) related to the tolerance to lipopolysaccharide (LPS) in rat alveolar macrophages.
METHODS: Alveolar macrophages obtained from 30 Wistar male rats were randomly divided into a control group, a LPS single-dose stimulation group and a LPS double-dose stimulation group. IL-10 and IL-18 mRNA in alveolar macrophages and the level of TNF-alpha, as indexes of LPS tolerance, were measured by semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) and enzyme linked immunoads orbeen assay (ELISA), respectively. The expression of TLR(4) was detected by Western Blot.
RESULTS: The level of TNF-alpha, and the mRNA for IL-10 and IL-18, and the protein of TLR(4) in the alveolar macrophages stimulated with single-dose LPS (100 ng/ml) were highly increased as compared with the control group [(0.760 +/- 0.030) micro g/L, 2.18 +/- 0.09, 1.83 +/- 0.07, 2.060 +/- 0.060, 148.3 +/- 1.4 vs (0.450 +/- 0.010) micro g/L, 1.16 +/- 0.04, 0.97 +/- 0.03, 1.320 +/- 0.020, 58.1 +/- 0.4 (P < 0.01)], while they were significantly decreased in the alveolar macrophages after re-stimulation with double-dose LPS (100 ng/ml and 500 ng/ml).
CONCLUSIONS: (1) The tolerance to LPS in alveolar macrophages can be induced by re-stimulation with LPS. (2) The down-regulated expression of TLR(4) is related to tolerance to LPS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12921646

Source DB:  PubMed          Journal:  Zhonghua Jie He He Hu Xi Za Zhi        ISSN: 1001-0939


  1 in total

1.  Time-course of Toll-like receptor 2 expression, as a predictor of recurrence in patients with bacterial infectious diseases.

Authors:  K Orihara; K Nagata; S Hamasaki; R Oba; H Hirai; S Ishida; T Kataoka; N Oketani; M Ogawa; E Mizoguchi; H Ichiki; C Tei
Journal:  Clin Exp Immunol       Date:  2007-05       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.